Unknown

Dataset Information

0

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.

ABSTRACT:

SUBMITTER: Chiorean EG 

PROVIDER: S-EPMC5117797 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.

Chiorean E Gabriela EG   Von Hoff Daniel D DD   Tabernero Josep J   El-Maraghi Robert R   Wee Ma Wen W   Reni Michele M   Harris Marion M   Whorf Robert R   Liu Helen H   Shiansong Li Jack J   Manax Victoria V   Romano Alfredo A   Lu Brian B   Goldstein David D  

British journal of cancer 20160922 9

Similar Datasets

Unknown Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.
| S-EPMC4947701 | biostudies-literature
Unknown Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
| S-EPMC6962478 | biostudies-literature
Unknown Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment.
| S-EPMC11199338 | biostudies-literature
Unknown Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer.
| S-EPMC10632451 | biostudies-literature
Unknown Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus <i>nab</i>-paclitaxel for Advanced Pancreatic Adenocarcinoma.
| S-EPMC8458827 | biostudies-literature
Unknown First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population.
| S-EPMC9724069 | biostudies-literature
Unknown Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
| S-EPMC9178436 | biostudies-literature
Unknown Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score-matched analysis.
| S-EPMC12639605 | biostudies-literature
Unknown Efficacy and safety of second-line nab-paclitaxel plus gemcitabine after progression on FOLFIRINOX for unresectable or metastatic pancreatic ductal adenocarcinoma: multicenter retrospective analysis.
| S-EPMC7257856 | biostudies-literature
Unknown Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma.
| S-EPMC9907047 | biostudies-literature